Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Increases By 33.1%

Posted by Latisha Jones on Feb 2nd, 2025

vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 22,500 shares, an increase of 33.1% from the December 31st total of 16,900 shares. Based on an average daily trading volume, of 29,400 shares, the days-to-cover ratio is currently 0.8 days. Currently, 1.5% of the company’s stock are short sold.

vTv Therapeutics Stock Performance

Shares of vTv Therapeutics stock opened at $15.62 on Friday. The company’s 50 day moving average is $14.76 and its 200 day moving average is $15.07. vTv Therapeutics has a twelve month low of $8.03 and a twelve month high of $30.99.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.88) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Alliance Global Partners began coverage on shares of vTv Therapeutics in a report on Monday, December 9th. They set a “buy” rating and a $35.00 price target on the stock.

Get Our Latest Research Report on vTv Therapeutics

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in vTv Therapeutics stock. FMR LLC purchased a new position in vTv Therapeutics Inc. (NASDAQ:VTVT – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned 5.92% of vTv Therapeutics at the end of the most recent quarter. 17.51% of the stock is owned by hedge funds and other institutional investors.

About vTv Therapeutics

(Get Free Report)

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.